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Abstract
Post-mortem analysis of brains from Parkinson’s disease (PD) patients strongly supports microglia activation and adaptive
immunity as factors contributing to disease progression. Such responses may be triggered by a-synuclein (a-syn), which is
known to be the main constituent of the aggregated proteins found in Lewy bodies in the brains of PD patients. To
investigate this we used a recombinant viral vector to express human a-syn in rat midbrain at levels that induced neuronal
pathology either in the absence or the presence of dopaminergic cell death, thereby mimicking early or late stages of the
disease. Microglia activation was assessed by stereological quantification of Mac1+ cells, as well as the expression patterns
of CD68 and MCH II. In our study, when a-syn induced neuronal pathology but not cell death, a fast transient increase in
microglia cell numbers resulted in the long-term induction of MHC II+ microglia, denoting antigen-presenting ability. On the
other hand, when a-syn induced both neuronal pathology and cell death, there was a delayed increase in microglia cell
numbers, which correlated with long-lasting CD68 expression and a morphology reminiscent of peripheral macrophages. In
addition T-lymphocyte infiltration, as judged by the presence of CD4+ and CD8+ cells, showed distinct kinetics depending
on the degree of neurodegeneration, and was significantly higher when cell death occurred. We have thus for the first time
shown that the microglial response differs depending on whether a-syn expression results on cell death or not, suggesting
that microglia may play different roles during disease progression. Furthermore, our data suggest that the microglial
response is modulated by early events related to a-syn expression in substantia nigra and persists at the long term.
Citation: Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia Acquire Distinct Activation Profiles Depending on the Degree of a-
Synuclein Neuropathology in a rAAV Based Model of Parkinson’s Disease. PLoS ONE 5(1): e8784. doi:10.1371/journal.pone.0008784
Editor: Mark R. Cookson, National Institutes of Health, United States of America
Received October 9, 2009; Accepted December 19, 2009; Published January 20, 2010
Copyright:  2010 Sanchez-Guajardo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from, The Swedish Research Council (K2007-61X-14552-05-3 to DK, www.vr.se), Lundbeck Foundation ( R9-A1061 to
MRR and R17-A1564 to VSG, www.lundbeckfonden.dk), the Danish Research Council (271-06-0261 to MRR, en.fi.dk/councils-commissions/the-danish-council-for-
independent-research/scientific-research-councils/medical-sciences), Danish Parkinson Foundation (to MRR, www.parkinson.dk), Nordic Center of Excellence in
Neurodegeneration (to DK and MRR). The funders had no role in study design, data collection and analysis, decision on publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mrr@biokemi.au.dk
Introduction
In the majority of cases, the etiology of sporadic Parkinson’s
disease (PD) still remains largely unknown. However, emerging
evidence suggests that multiple factors, both genetic and acquired,
contribute to neurodegeneration of the dopaminergic cells of the
substantia nigra (SN) in these patients [for review see [1,2]]. There
are several lines of study indicating that activation of microglia,
with subsequent production of pro-inflammatory cytokines,
aggravates the neurodegenerative process in PD [3,4]. In vivo
imaging studies using PET ligands have shown microglial
activation in patients with PD [5,6]. Here, not only the number
of activated microglia cells is increased, but molecules related to
inflammation are elevated as well. In the nigro-striatal system, pro-
inflammatory cytokines, such as tumor necrosis factor (TNF)-a,
interleukin (IL)-1b and interferon (IFN)-c, are increased. These
have been found to co-localize with microglia in histological data,
and are increased in serum of PD patients. [7,8,9,10,11,12].
Importantly, these cytokines can act directly on dopaminergic cells
and lead to activation of caspases [13,14,15,16]. Last but not least,
microglia activation can lead to free-radical formation, which can
contribute to the increase in oxidative markers found in PD [17].
Taken together, the data suggest that the persistent activation of
microglial cells is dynamically involved in the disease’s progression.
Although it is tempting to assume that this event could contribute
to neuronal damage and cell death in PD, it is also possible that
the microglia population exerts a protective effect on neurons in
the SN, thus delaying neurodegeneration progression.
Another determining factor in PD etiology is a-synuclein (a-
syn). Missense mutations in the a-syn gene have been identified to
cause autosomal dominant familial PD [18,19,20]. Furthermore,
the multiplication of the a-syn gene leads to PD, indicating that a
mere over expression of the protein can lead to dopaminergic cell
death [21,22,23,24]. In both familial and non-familial cases, where
no genetic mutations are found, a-syn is the major component of
Lewy bodies (LBs) [25]. The relationship between a-syn pathology
and activation of microglia remains poorly studied. It is however
possible, that a-syn plays a role in microglia activation as shown by
several in vitro studies [26,27,28]. Zhang and colleagues showed
that depletion of microglia diminished the dopaminergic cell death
induced by exposure to aggregated a-syn in a cell culture system
[29]. Nitrated a-syn has been suggested to play an important role
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well as the induction of immunity [33].
Although the presence of neuroinflammation in PD has long
been accepted, the contribution of the adaptive immune system is
still poorly defined. Several findings in PD patients support its role
in the disease process: the presence of T cells in the SN of patients;
the existence of IgG that react with dopaminergic tissue; and
dopamine derived oxidative products in serum and CSF of PD
patients [34,35,36]. Class I and II major histocompatibility
complex (MHC), essential molecules for antigen presentation,
are increased in the striatum and SN, respectively, of PD patients
[14,37]. Indeed, correlation between MHC class II antigen
expression and a-syn deposition has been observed in post-
mortem nigral specimens from PD patients [38]. Moreover,
antibodies against a-syn were found in patients suffering from
familial PD [39]. Together suggesting that a-syn may be the
antigen that induces the immune response.
In the present study we use a recently described progressive
neurodegeneration model of PD based on over-expression of
human wild type (wt) a-syn mediated by injection of recombinant
adeno-associated virus (rAAV) directly into the SN [40,41,42].
We have investigated the temporal profile of microglia activation
Figure 1. Tyrosine hydroxylase immunostaining. TH immunohistochemical staining of striatal (A-I) and nigral sections (J-L) from animals of
the GFP group (A, D, G and J), the a-syn-neurodegeneration group (B, E, H and K), or the a-syn-cell death group (C, F, I and L) at 4 weeks (A-C),
8 weeks (D-F) or 15 weeks (G-L) post- rAAV2/5 injection. GFP expressing animals showed dense dopaminergic fiber staining in striatum (A, D and G)
and numerous TH+ neurons in SN (J) that did not change after 15 weeks. Animals in the a-syn-neurodegeneration group showed an apparent
decrease in TH+ fiber staining in striatum at 8 weeks that further decreased at 15 weeks (E and H). After 8 weeks, numerous TH+ fibers appeared
thicker and/or with small round formations, which became bigger after 15 weeks (arrows in E and H). However, the number of TH+ neurons in SN (K)
remained similar to control levels (both contralateral side (not shown) and to GFP in J) after 15 weeks. In the cell death group a-syn expression lead
to loss of TH fibers that was already apparent at 4 weeks; with time fibers became thicker and more apparent, although less numerous (C, F and I).
TH+ fibers in these animals showed thickening and pathological round formations from early time points that increased with time (arrows in C, F and
I). This was accompanied by a significant decrease of TH+ neurons of similar magnitude at 4, 8 (data not shown) and 15 weeks (L). Scale in I: 40 mm,
applies to A-I. Scale in L: 100 mm, applies to J-L.
doi:10.1371/journal.pone.0008784.g001
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nigral dopaminergic cell death. We designed an in vivo
experimental approach, where animals expressed a-syn in the
nigro-striatal pathway at such levels as to achieve pathological
mishandling of a-syn that resulted in significant cell death in SN.
In parallel, a second group of animals expressed levels of a-syn
that resulted in pathological accumulation of a-syn and nigro-
striatal degeneration but where cell death in SN was absent.
Microgliosis and expression of activation related molecules were
analyzed at different time points. Our data suggest that a-syn
expression not only leads to persistent microglia activation, but
that depending on the degree of induced neuropathology distinct
microglial responses will occur. a-Syn expression levels capable of
inducing dopaminergic cell death correlate with the long-term
induction of macrophagic microglia; whereas, at levels where
only neurodegeneration is taking place, we have microglia with
antigen presenting capabilities.
Methods
Animals
Adult female Sprague Dawley rats (Taconic, Denmark) of 225–
250 g (at the time of surgery) were housed three to a cage with ad
libitum access to food and water during a 12 hr light/dark cycle. All
procedures were approved by the Ethical Committee for the use of
laboratory animals in Aarhus University.
Viral vectors
The vectors contain the transgene of interest [human wt a-syn,
or the enhanced green fluorescent protein (GFP)] under the
control of the synthetic chicken beta actin (CBA) promoter
[40,41,43]. rAAV2/5 vectors were purified by iodixanol step
gradients and ion-exchange as described in detail elsewhere [44].
The final titers of the concentrated vector stocks were as follows: a
first rAAV2/5-wild type a-syn (6.2610
13 genome copies/ml), a
second rAAV2/5-wild type a-syn (6.7610
13 genome copies/ml),
and rAAV2/5-GFP (7.9610
12 genome copies/ml) as determined
by quantitative PCR.
Surgical procedure
Surgery was conducted under anesthesia using a stereotaxic
frame (Stoelting, Wood Dale, IL, USA) and a 5 ml Hamilton
syringe fitted with a glass capillary (outer diameter of 60–80 mm).
Animals received a single 2 ml injection of either first, second
rAAV2/5-a-syn or rAAV2/5-GFP into the right SN at the
following coordinates: 5.2 mm posterior, 2.0 mm lateral to
bregma, and 7.2 mm ventral relative to dura. Vector stocks were
injected at a rate of 0.2 ml/30 s. The needle was left in position for
an additional 5 mins after the infusion was completed before being
slowly retracted. Animals were then sutured with metal clips and
returned to their cage where food and water were freely available.
Immunohistochemistry
Under pentobarbital anesthesia the animals were perfused
through the ascending aorta with physiological saline, followed by
4% ice-cold para-formaldehyde. The brains were post-fixed in the
same solution for 2 hr, transferred to 25% sucrose, and sectioned
on a freezing microtome at 35–40 mm in the coronal plane.
Immunohistochemical stainings were performed on free-floating
sections using the following antibodies: anti human a-syn (rabbit,
against epitope 116–131, 1:4000); and of mouse origin: tyrosine
hydroxylase (TH) (Chemicon, Temecula, CA, 1:2000), ED1
(CD68, Serotec, 1:200), Mac1 (CD11b, Serotec, 1:500), MHC II
(Serotec, 1:250), CD3 (Serotec, 1:500), CD8a (Serotec 1:500) and
CD4 (domain 1, Serotec, 1:500). The sections were quenched for
10 min in a solution of 3% hydrogen peroxide/10% methanol.
Sections were rinsed three times in potassium-phosphate buffer
(KPBS) between each incubation period. All incubation solutions
contained 0,25% Triton X-100 in KPBS. One hour of pre-
incubation with 5% appropriate normal serum was followed by
overnight incubation at room temperature of the primary antibody
in 2,5% normal serum. Thereafter the sections were incubated for
2 hr with the appropriate biotinylated secondary antibody (1:200,
Vector Laboratories, Burlingame, CA) in 1% normal serum,
followed with 1 hr incubation with avidin-biotin-peroxidase
complex in PBS (ABC Elite, Vector Laboratories, Burlingame,
CA). Visualization was done using 3,3-diaminobenzidine and
0.01% of hydrogen peroxide for TH and a-syn visualization, and
0.001% for the others. The sections were mounted in chrome-
alum-coated glass slides and cover-slipped. During cover-slipping
some sections were counter-stained with cresyl blue.
Stereological quantification of cell numbers in the
midbrain
The unbiased stereological estimation of the total number of
TH+ cells in SN was made using the optical fractionator as
previously described [41]. This sampling technique is not affected
by tissue volume changes and does not require reference volume
determinations. Sampling was done using the NewCAST software
from Visiopharm. A low power objective lens (1.25x, SPlan) was
used to delineate the borders of the SN at all levels in the
rostrocaudal axis. The medial border of the SN and lateral border
of the VTA was defined by a vertical line passing through the
medial tip of the cerebral peduncle (and by the medial terminal
nucleus of the accessory nucleus of the optic tract, when present in
the sections). Ventral border followed the dorsal border of the
cerebral peduncle, thereby including the TH-positive cells in pars
reticulata (SNr), and the area extended laterally to include the pars
lateralis in addition to the pars compacta (SNc). The sections used
for counting covered the entire SN from the rostral tip of the pars
compacta back to the caudal end of the pars reticulata. This
typically yielded 8–9 sections in a series. The counting frame was
placed randomly on the first counting area and systematically
moved through all counting areas until the entire delineated region
Figure 2. Dopaminergic cell survival in Substantia Nigra. Graph
illustrates the estimation of total dopaminergic neurons in SN
(expressed as % of control, contralateral side values) using stereological
tools in all groups and time points. A significant decrease of the number
of TH+ cells was observed in the a-syn-cell death group at all time
points. Two-way ANOVA [F (8,46)=6.18, p,0.01] followed by individual
contrast. One-way ANOVA: * ,0.05 and ** ,0.01 different from the GFP
group at the same time point, effect of group at 4 weeks [F (2, 14)=9.3,
p,0.01], at 15 weeks [F (2, 16)=9.3, p,0.01], at 15 weeks [F (2,
14)=4.1, p,0.05] followed by a Dunnett’s post-hoc analysis.
doi:10.1371/journal.pone.0008784.g002
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X-Y step length between 100 and 200 mm, so that about 100–200
TH-positive cells were counted in each side of the SN. Actual
counting was done using a 40x objective (NA 0.75). The estimates
of the total number of neurons were calculated according to the
optical fractionator formula and a coefficient of error ,0.10 was
accepted [45,46].
For the microglia quantification, similarly adjacent (7–8) serial
sections were used. An observer blind to the samples identity
quantified the number of Mac1 positive cells in the SN as
described above (Leica microscope at a 40x magnification). Here
the X-Y step length used was between 300–400 mm in order to
count 100–200 Mac1+ cells in each side of the SN. A positive cell
was defined as a nucleus covered and surrounded by Mac1
immunostaining.
Morphological characterization
During the stereological analysis, the morphology of each
Mac1+ cell was scored according to the length and thickness of
their processes, the characteristics of their cell body and the look of
the nucleus. Four cellular profiles were defined: Type A, cells with
no visible cytoplasm, a round dense nucleus, and with long thin
processes with little branching; these were deemed ‘‘resting’’
microglia. Type B, cells with a visible thin cytoplasm surrounding
a dense nucleus; processes are very long and thin, with many
branches of less defined edges. Type C, cells with elongated and
irregular body, enlarged and less defined nucleus, and with shorter
re-defined processes of varying thickness and little branching.
These cells are reminiscent of antigen presenting cells. Type D,
have a big cell body merging with the processes, the nucleus
occupies most of the cell body and is not always distinguishable;
processes are few thick and short. These cells look indistinguish-
able from peripheral macrophages. (See results section for further
description)
Microscope analysis of brain sections
An observer blind to the origin of the section, analyzed one
section from the striatum and one from SN of each animal per
Figure 3. Transgene expression. Transgene immunostaining at striatal (A–C, E–G and I–K) or nigral level (D, H and L) from animals of the GFP
group (A–D), a-syn-neurodegenerative group (E–H), and a-syn-cell death group (I–L) at 4 weeks (A, E and I), 8 weeks (B, F and J), or 15 weeks (C,
D, G, H, K and L) post- rAAV2/5 injection. GFP immunostaining was observed in the ipsilateral side of animals injected with GFP-rAAV2/5, as a dense
fiber staining where no apparent pathology was observed (A, B and C). In the midbrain we observed neurons expressing GFP both in SNc (arrows)
and SNr (arrowheads) that remained after 15 weeks (D). Animals in the a-syn-neurodegeneration group showed dense fiber immunostaining for
human-a-syn at 4 weeks (B). Fiber staining decreased progressively with the concomitant appearance of pathological formations (F and J). At
8 weeks numerous round a-syn+ formations were observed (arrows in F). With time these formations became bigger (arrows in J) and thickening of
a-syn+ fibers was observed (arrowheads in J). At the nigral level, numerous a-syn+ neurons in SNc persisted after 15 weeks (arrows in H). In animals
of a-syn cell death group, fiber staining was lower than in the other a-syn group at 4 weeks (I vs. E). Progressively a-syn+ fibers became thicker and
less abundant in striatum (arrowheads in I–K). In addition, a-syn+ pathological formations were already apparent at 4 weeks, they persisted and
became bigger as time progressed (arrows in I–K). In the midbrain we observed a-syn+ neurons both in SNc (arrows) and SNr (arrowheads) that
remained after 15 weeks (L). There was a lower number of a-syn+ neurons in SNc than in the a-syn-neurodegeneration group (L vs. H). Scale:
100 mm, in A applies to A–C, E–G and I–K; in D applies to D, H and L.
doi:10.1371/journal.pone.0008784.g003
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10x and 40x and the extension of the marking was scored as
described in the results section. For CD3, CD4 and CD8, the
observer counted the number of positive cells within the section at
20x and 40x.
Statistics
Statistical comparison of data was performed using JMP
statistical software v. 5.01 (SAS Institute Inc. Cary, NC, USA).
Time and group interactions were analyzed using two-way
factorial ANOVA, when significant followed by Tukey HSD
post-hoc analysis. When appropriate, individual time points within
groups were compared by one-way ANOVA followed by Tukey-
Kramer or Dunnet’s post-hoc analysis. For statistic analysis on
scores (MHCII and CD68) non-parametric oneway ANOVA
followed by Van der Waerden post-hoc analysis was performed.
Results
a-Synuclein induces neurodegeneration and
dopaminergic cell death
In order to study the role of microglia as a function of human a-
syn expression, we decided to follow the microglial response in two
different scenarios: one where a-syn expression did not lead to
dopaminergic cell loss, but only to pathological accumulation of
the protein and striatal fiber loss; another where a-syn induced a
progressive cell death in the SN.
To confirm our experimental design we performed stereological
quantification of TH+ neurons in SN in all groups at 3–4, 8 and
15 weeks. As anticipated, one group of animals, termed a-syn-
neurodegeneration, did not show any significant loss of dopami-
nergic cells when compared to GFP control animals (Figure 1J &
K and Figure 2). However, the other group, termed a-syn-cell
death, showed significant cell death as soon as 4 weeks that
remained unchanged at 8 and 15 weeks (Figure 1L and Figure 2).
At striatal level, dopaminergic fiber density decreased as expected
in these animals. The remaining fibers appeared thicker and with
big TH+ round formations that increased progressively (Figure 1C,
F & I). Interestingly, in the animals where a-syn failed to induce
neuronal cell loss, we observed a decrease in fiber density and
progressive pathological formations (Figure 1B, E & H). In the
control GFP animals, no change was observed as compared to the
contralateral side (Figure 1A, D & G).
The criterion followed here to match the two a-syn vectors was
the rAAV titer, i.e. the numbers of viral particles per ml of each
rAAV batch. However, the level of transgenic protein expression per
infected cell will depend not only in the number of physical particles
injected, but also in the ability of these particles to infect the cell and
express the protein (viral infectivity). This means that despite having
similar titers, two vector batches produced in two different
production runs may result in different infectivity per physical
particle,potentiallyleading todissimilarexpressionlevels.Therefore,
it is possible that two vectors with similar physical titer result in one
case in an a-syn expression level that induced cell death while in the
other case merely protein accumulation but not frank cell loss.
a-Synuclein induces pathological formations in the
striato-nigral neurons independently of neuronal death
Local injection into the midbrain of rAAV-a-syn resulted in
transduction of nigral dopaminergic cells and expression of human
a-synthroughout the nigro-striatalsystemasexpected (Figure 3E-L).
Regarding the nigral dopaminergic neurons, animals in the a-syn
neurodegeneration group displayed after 4 weeks numerous a-syn+
cellbodiesthatwereconfinedtothe SNc,thesepersisted at 15 weeks
Figure 4. Microglia morphology and cell number. (A) Animals
expressing GFP, or a-syn at levels that caused either neurodegeneration
or cell death were killed at 4 (white bars), 8 (black bars) and 15 (grey
bars) weeks after surgery. SN resident microglia cell numbers and
morphology were stereologically analyzed at each time point. Data
represents average increase of Mac1+ microglia cell number in the
ipsilateral SN as compared to the contralateral SN (n=5–6) + S.E.M.
Two-way ANOVA [F (8,45)=11.2, p,0.0001] followed by Tukey HSD
post-hoc analysis. * or # p,0.05 ** p,0.01 (*) compared to the GFP
control group at same time point; (#) compared to the other a-syn
group at same time point. (B) The four morphologies of microglia are
represented: Type A, corresponding to resting microglia: cells with a
round dense nucleus without a visible cytoplasm surrounding it, and
with long thin processes. Type B: there is a visible small thin cytoplasm
around a dense nucleus, processes remain thin, but are longer with
many branches of less defined edges. Type C: the cell body becomes
elongated and irregular, with an enlarged and less defined nucleus,
processes become shorter of varying thickness and little branching.
Type D: the cell body is big and dark, merging with thick short
processes; the nucleus occupies most of the cell body and is not always
distinguishable. Scale in type D: 20 mm, applies to all. (C) Stereological
quantification of each morphology type is depicted as the average
percentage distribution per group as a function of time. Two-way
ANOVA, when significant followed by Tukey-Kramer post-hoc analysis.
# p,0.05 compared to the other a-syn group at same time point;
*p ,0.05, ** p,0.01 compared to the other two groups at same time
point.
doi:10.1371/journal.pone.0008784.g004
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human a-syn was observed in striatum (Figure 3E). Starting at
8 weeks, these fibers showed small pathological accumulations that
increased in occurrence and thickness with time, while fiber density
progressively decreased (Figure 3E-G). In comparison, animals with
apparent dopaminergic cell death exhibited fewer a-syn+ cells in the
SNc at all time points, presumably due to the significant cell loss
observed at 4–15 weeks (Figure 3L). In this group, the density of a-
syn+ fibers was lower at all time points and as soon as 4 weeks,
numerous pathological a-syn+ accumulations and thickening of the
striatal terminals were observed (Figure 3I). Although the number of
a-syn+ cells in SN remained unchanged at all points, fibers in
striatum decreased with time, with the concomitant pathological
accumulation of a-syn in the remaining fibers (Figure 3J & K). GFP
expressing animals showed a strong GFP immunostaining in cells of
the SNcthatpersistedat15 weeks (Figure3D);as wellas,densefiber
immunostaining at striatal level that did not decrease with time nor
showed any pathological abnormal accumulation (Figure 3A–C).
We have thus generated two sets of animals where we observed
progressive nigrostriatal degeneration and a-syn accumulation, but
where robust cell death was only induced in one of them. We will
refer hence to these groups as a-syn-neurodegeneration and a-syn-
cell death.
Modulation of microglia morphology and cell number in
Substantia Nigra is dependent on the degree of
a-synuclein induced pathology
The microglia population in midbrain was analyzed by
stereological quantification of Mac1+ cells at all time-points.
Numbers were normalized to the number of microglia in the
contralateral uninjected side of each animal. Only cells where a
nucleus (counterstained with cresyl violet) was completely covered
and surrounded by Mac1+ staining were considered positive cells.
Four weeks after surgery there was an increase in microglia cell
numbers in the injected SN in all groups. However, the increase
was significantly higher in the a-syn-neurodegeneration group
(Figure 4A), where numbers gradually decreased to control levels
at 8–15 weeks. In contrast, when cell death occurred, microglia
cell numbers peaked at 8 weeks, to eventually drop significantly
and return to basal levels at 15 weeks (Figure 4A). It is interesting
to note that all the animals of a-syn-cell death group had weak
Mac1+ staining at 4 weeks.
During the stereological analysis we further quantified microglia
morphologically. Four cellular profiles (Figure 4B) were defined
according to the length and thickness of their processes, the
characteristics of their cell body and the look of the nucleus as
detailed in Material and Methods. Type A, were deemed ‘‘resting’’
microglia as they were the dominant type of microglia in the
contralateral side of the brain, as well as brain areas other than the
SN. Type B, were usually found isolated, the end of their processes
in association with many Mac1- nuclei. Type C, were often seen in
association with blood vessels, some of them were clearly inside the
lumen of the vessel (Figure S1C & D). They usually had Mac1-
nuclei in direct contact with their processes but seldom with the
cell body; and although often close in space to each other, they
never formed clusters. These cells are reminiscent of antigen
presenting cells. Type D, were seldom found isolated or in contact
with blood vessels, they tended to form clusters and always had
multiple nuclei associated with the cell body (visible at different
focus planes, data not-shown). These cells look indistinguishable
from peripheral macrophages.
We observed that in all groups at 4 weeks type D (macrophagic)
cells constitute over 40% of the microglia population (Figure 4C).
At 8 weeks the most distinctive event is the significant prevalence
of type D microglia in the a-syn-cell death group, whereas both
GFP and a-syn-neurodegeneration show similar profile distribu-
tion (Figure 4C). At long term, in the a-syn-cell death group, type
D (48%) still constitutes the most abundant microglia, while in the
a-syn-neurodegeneration animals, type B constitutes over 50% of
the population. At this time point, 37% of the microglia in GFP
have returned to their resting stage (Type A, Figure 4C).
Microglia up-regulates distinctive activation markers
depending on the degree of a-synuclein induced
neurodegeneration
To correlate morphology to function, we studied the levels of
expression of CD68 (ED1) as a marker for macrophagic function,
and MHC II for antigen presentation ability (Table 1), both being
practically undetectable in naı ¨ve/healthy animals. We assessed the
level of up-regulation of CD68, where 3 scores were given based
on the number of CD68+ cells and their localization (Figure 5). In
the GFP group, at 4 weeks we observed CD68 positive staining of
varying degree (Figure 5 & Table 1), but CD68 expression was
absent at 8–15 weeks, suggesting that the unspecific response to
the viral vector injection was resolved. In the a-syn–neurodegen-
eration group, at 4 weeks, CD68+ microglia were mainly found
scattered throughout the SNc. At this point GFP animals showed
significantly more CD68 expression, suggesting that viral vector
injection and infectivity plays a role in the initial response (Table 1).
At later time points, differing from the GFP group, some animals
in a-syn-neurodegeneration still showed scattered CD68+ cells,
though this was not significant (Table 1). In contrast, when a-syn
expression led to cell death, there was a significant up-regulation of
the macrophagic marker at 4 weeks, where we observed an intense
dense punctuated staining throughout the whole SN. Expression
persisted with time, but became restricted to the SNc at 8 weeks
(Table 1 & Figure 5A). Due to the intracellular vesicular
localization of the CD68 receptor, it was not possible to directly
assess the morphology of the cell expressing it by means of its
staining pattern (Figure 5B). However, its high up-regulation
correlates with SN where the predominant microglial morphology
is of type D.
When MHC II expression was analyzed, all animals in the GFP
group showed a varying degree of MHC II+ cells at 4 weeks.
Table 1. Analysis of expression levels of microglia activation
markers induced by a-synuclein neuropathology in Substantia
Nigra.
4 weeks 8 weeks 15 weeks
CD68
GFP 2.0061.58
# 0.0060.0 0.0060.0
Neurodegeneration 0.0060.45 0.0060.45 0.0060.45
Cell death 2.0060.53
# 2.5061.28
##,* * 2.0060.53
##,* *
MHC II
GFP 2.0061.58 1.0061.58 0.0061.05
Neurodegeneration 4.5060.91
* 4.0060.91
* 2.5060.91
Cell death 4.0060.53 4.0061.28
* 3.0062.10
An observer blind to the sections identity scored expression levels based on
number of positive cells and area covered, as explained in Figure 3. CD68: 0–3,
MHC II: 0–5. Numbers are median 695% confidence interval. Statistical analysis:
non-parametric oneway ANOVA followed by Van der Waerden post-hoc
analysis. * or # p,0.05, ** or ## p,0.01 (*) compared to GFP control, (#)
compared to the neurodegeneration group.
doi:10.1371/journal.pone.0008784.t001
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showed few MHC II+ cells in SNc (Table 1 & Figure 6A). In
animals of the a-syn-neurodegeneration group, we observed at
4 weeks a significant robust up-regulation of MHC II expression
in the ventral midbrain, where the area immunostained for MHC
II covered the full SN (both SNc and SNr) (Table 1 & Figure 6A).
Figure 6. MHC II microglial expression. Photos show representative nigral sections immunostained for MHCII. The level of MHC II expression in
microglia was scored 0–5 (A): Score 0, no positive cells; Score 1, few isolated cells; Score 2, scattered throughout the SNc or few clusters; Score 3,
throughout the SNc; Score 4, throughout the SN; Score 5, saturation of the SN. (B) High magnification photo of the insert showed in A Score 4. The
most abundant MHC II+ microglia morphology corresponded to microglia type B (arrow). (C) In the groups expressing a-syn, we also observed
numerous small MHC II+ round cells at 4 (not shown) and 8 weeks. (D–E) MHC II+ cells in association with blood vessels. Occasionally we saw MHC II+
cells, which seemed to be inside of the vessel’s lumen (arrowhead in D); in other cases MHC II+ cells seemed to penetrate and/or surround the
vessel’s wall (arrowheads in E). The images come from, C and D: neurodegeneration at 4 weeks (Score 5), E: neurodegeneration 8 weeks (Score 3).
Scale in Score 0: 90 mm, applies to all in A. Scales in B: 10 mm, in C: 40 mm and in D&E: 20 mm.
doi:10.1371/journal.pone.0008784.g006
Figure 5. CD68 microglial expression. The levels of CD68 expression were scored 0–3 (A): Score 0, non or 1–3 isolated positive cells; Score 1, few
scattered cells; Score 2, throughout the SNc; Score 3, throughout the SN. Scale in Score 3: 80 mm, applies to all in A. (B) Higher magnification of
representative CD68+ immunostaining. Notice how the intracellular vesicular localization of the protein (arrowheads) makes it difficult to determine
how many positive dots belong to one microglia. Scale in B: 13 mm (top) and 20 mm (bottom).
doi:10.1371/journal.pone.0008784.g005
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8 weeks, then decreased and became restricted to SNc at 15 weeks
(Table 1 & Figure 6A). In the a-syn-cell death group, MHC II up-
regulation was significantly elevated in all animals at 4–8 weeks,
although it never reached the levels of expression of the a-syn-
neurodegeneration group. Expression remained elevated at the
level of the SNc in 3 out of 5 animals at 15 weeks (Table 1 &
Figure 6A). MHC II+ microglia exhibited in all groups and at all
time points type B morphology (Figure 4B), although at 4 weeks a
fraction of the cells exhibited Type C morphology (not shown).
It is interesting to note that we observed round small cells, which
stained positive for MHC II (Figure 6C). Although some cells
where observed in a fraction of the a-syn-neurodegeneration
animals at 4–8 weeks and occasionally in the GFP, these cells were
mainly present in the a-syn-cell death group (all animals, all time
points).
Microglia cells associate with blood vessels in a-synuclein
expressing animals
During the stereological quantification of serial sections of SN we
also noted the appearance of enlarged blood vessels (as compared to
those observed in the control side) and whether such vessels where
associated to any specific type of cells. Animals of the a-syn-cell
death group showed consistently more enlarged blood vessels than
the other two groups at 4 weeks (average of 16 enlarged blood
vessels vs. 5 per SN). Mac1 low/neg nuclei were associated with and
Figure 7. T cell infiltration. Photos show SN of animals immunostained with antibody against CD3 in order to address T cell infiltration (A–L).
CD3+ cells were found either isolated (A), associated with blood vessels (B) or clustered together (C). Immunostaining appeared homogeneously
distributed in the cell body (arrowheads in A and B) or punctuated (arrowheads in C). Scale: 40 mm, applies to A–C. The small panels show individual
CD3+ cells from A (D–F), B (G–I) and C (J–K) at high magnification. (L) Panel shows high magnification of CD3+ cells with punctuated staining
without counterstaining in order to appreciate better the staining pattern. Scale: 10 mm, applies to D–L. Photos were taken from sections of animals
of the following groups, A: cell death 4 weeks, B: cell death 8 weeks, C+L: neurodegeneration 15 weeks. (D) Graph shows average (bar) and individual
numbers of CD3+ cells found in one SN section at 8 weeks. These are plotted per animal in each group.
doi:10.1371/journal.pone.0008784.g007
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in the a-syn-neurodegeneration group all associated nuclei were
Mac1+ (Figure S1C & D). We always observed Mac1+ Type C cells
associated with blood vessels at 8 weeks in both a-syn groups
(average of 4 in both groups). At 15 weeks, both a-syn groups had
few increased blood vessels with mixed nuclei. In the GFP group we
saw few cells, of mixed type, associated with blood vessels at 4 wk
(anaverage of2 enlarged blood vesselwith associatednucleiperSN)
and none at 8–15 weeks.
In addition, at 4–8 weeks, we observed MHC II+ cells
associated with and within blood vessels in both a-syn groups
(Figure 6D & E). In the GFP group this was seen only occasionally
and with not specific time correlation (not shown).
Recruitment of the adaptive immune system depends on
the extent of microglia activation
As a specific subset of microglia up-regulate MHC II, pointing
to a possible implication of the adaptive immune system, we looked
for T cell (CD3+) infiltration into the SN. CD3 is a multimeric
membrane kinase that is associated with the T cell receptor (TCR).
In our study we observed two patterns of CD3 staining: first, when
found isolated or in association with a blood vessel the staining was
uniform, giving a round and well-defined staining (Figure 7A–B &
D-I). In contrast, when found in clusters, the staining tended to be
punctuated, suggesting CD3 clustering, and the individual cell was
difficult to determine (Figure 7C & J–L).
Analysis of the number of CD3+ cells per section of SN revealed
that T cell infiltration is very variable. In the GFP animals, at all
time points, only 2 (out of 5) animals showed CD3+ cells in SN
(average 6 SEM of numbers in the ipsilateral SN: 4 weeks
7.264.4; 8 weeks 5.263.4; 15 weeks 5.064.2). While in the a-syn-
neurodegeneration group, CD3+ cells were observed in half of the
animals at 4 weeks, increasing to 5 out of 6 at 8–15 weeks (average
6 SEM of numbers in the ipsilateral SN: 4 weeks 2.361.9;
8 weeks 2.560.7; 15 weeks 5.663.4). Interestingly, the presence of
CD3+ cells was consistently seen in all animals in the a-syn-cell
death group at 4–8 weeks and only one animal of the group did
not show T cells at 15 weeks (average 6 SEM of numbers in the
ipsilateral SN: 4 weeks 6.662.6; 8 weeks 12.062.6; 15 weeks
5.663.5). Indeed at 8 weeks, the number of CD3+ cells was
Figure 8. CD4 and CD8 T cell infiltration. Photos show SN sections of an animal of the cell death group immunostained with antibody against
CD4 (A and C) and CD8 (B and D). The small panels show insets in A (C) and in B (D) at higher magnification. Scale: 50 mm, applies to A–B, 10 mm
applies to C–D. (E) Graph shows average (dash) and individual numbers of CD4+ cells found in one SN section per animal of each group plotted per
time. Two-way ANOVA [F (8,42)=4.1, p=0.001 effect of group and time interaction] followed by Tukey HSD post-hoc analysis. ## or c ¸p ,0.01 (##)
compared to the other a-syn group at same time point; ({{) different to the next time point of the same group. (F) Graph shows average (dash) and
individual numbers of CD8+ cells found in one SN section per animal of each group plotted per time. Two-way ANOVA [F (8,41)=4.3, p=0.001 effect
of group and time interaction] followed by Tukey HSD post-hoc analysis. (**) p,0.01 compared to all other groups at all time point.
doi:10.1371/journal.pone.0008784.g008
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this group and at this time point we saw CD3+ cell association
with blood vessels. One should note that, in the a-syn-cell death
group, staining was mainly of the isolated type, whereas in the a-
syn-neurodegeneration group it was of mixed type and in the GFP
mainly punctuated.
T cell infiltration was further analyzed to determine if the
observed T cells were helper T cells (CD4+) or cytotoxic T cells
(CD8+) (Figure 8). Our analysis revealed that the helper T cell
response was of the same magnitude in both a-syn groups,
however they were recruited with different kinetics. While a-syn
expression in the absence of cell death correlated with an early
prominent recruitment of CD4+ cells that disappeared after
15 weeks; in the cell death group, helper T cells peaked at 8 weeks
and remained present, although at lower levels, after 15 weeks
(Figure 8E). GFP animals showed a moderate infiltration that fully
disappeared with time (Figure 8E).
Regarding cytotoxic T cells, we observed a low level infiltration
of CD8+ cells in the a-syn-neurodegeneration group at 4 weeks
that remained through time (Figure 8F). This response was
markedly different in the animals were a-syn induced cell death.
Here cytotoxic T cell infiltration was first observed at 8 weeks
and it was of significant higher magnitude than the other groups.
However, at 15 weeks the numbers of CD8+ T cells were similar
in both a-syn groups (Figure 8F). GFP animals showed
consistently less CD8+ cells than the a-syn groups at all time
points (Figure 8F).
MHCII+ is up-regulated in the striatum of animals
expressing a-synuclein
We also studied the microglia status in the striatum, which is the
area that shows the first signs of neurodegeneration and is distant
from the injection site. For this we stained for CD3, CD68 and
MHC II. Neither apparent up-regulation of CD68 nor presence of
CD3+ cells was observed in any group at striatal level (not shown).
However, in the a-syn-neurodegeneration group (4 and 8 weeks),
numerous MHC II+ microglia clustered throughout the ipsilateral
striatum in 50% of the animals (Figure 9A), while in the remaining
ones, MHC II expression was of varying degree. Although this did
not reach significance at this time point (data not shown), at
15 weeks, the a-syn-neurodegeneration group showed significantly
more MHC II+ cells than the other groups (Figure 9D). However
at this point, the number of cells and clusters were lower than at
earlier points (Figure 9B). In the a-syn-cell death group, only 2 (out
of 5) animals at each time point exhibited more MHC II+ cells
Figure 9. MHC II expression in the Striatum. Photos show representative striatal sections immunostained for MHC II from animals in the a-syn
neurodegeneration (A–B) or cell death group (C). In the neurodegeneration group we saw an up-regulation of the molecule throughout the striatum
at 4 weeks (A). At 8 weeks, expression persisted but had diminished to several isolated cells or small clusters (B). In the cell death group, we only
observed few isolated weakly stained positive cells at 8 weeks (C). Graph shows average (bar) and individual MHC II+ cells numbers found in one
striatum section at 15 weeks. These are plotted per animal in each group (Contralateral vs. Ipsilateral) (D). One-way ANOVA when significant followed
by Tukey-Kramer post-hoc analysis, (**) p,0.01 compared to ipsilateral site of the other two groups.
doi:10.1371/journal.pone.0008784.g009
a-Synuclein and Microglia
PLoS ONE | www.plosone.org 10 January 2010 | Volume 5 | Issue 1 | e8784that in the contralateral side. These were isolated lightly stained
MHC II+ cells (Figure 9C). GFP animals only showed occasional
lightly stained MHC II+ cells in both ipsi- and contralateral
striatum at all time points (not shown).
Discussion
We have previously shown that overexpression of human a-syn
in rat and monkey midbrain results in development of a
progressive dopaminergic neuropathology, leading to neuronal
loss in SN and fibers in the striatum. This is accompanied by
pathological accumulation of a-syn in cell bodies and fibers
[41,42]. In the present study, we believe we were able to mimic
both early and late stages of PD: where striatal dopaminergic fiber
loss, thickening of the fibers and pathological accumulation of a-
syn was observed in both groups; but where a-syn only induced
cell loss in the SN in one of the groups. This suggests that a-syn
mishandling is happening in both groups and that this results in a
neurodegenerative process that begins in the neuronal terminal.
We demonstrate that the microglial response is distinct and
specific to each time point. Indeed, when a-syn induced cell death
microglia acquired a predominant macrophagic phenotype. This
correlated with the elevated expression of the phagocytic marker
CD68 and recruitment of the adaptive immune system, as judged
by the significant presence of CD8+ cells. While a-syn neurode-
generation that did not cause cell death, induced microglia with
thin elongated branched dendrites that correlated with high MHC
II expression in both SN and striatum. This suggests that, during
the initial stages of a-syn induced neurodegeneration, microglia
acquire an antigen presenting cell phenotype.
Microglia, as the resident innate immune cells in the CNS, are
the surveyors of the brain, constantly moving and scanning their
surroundings for damaged neurons, functional state of synapses,
plaques and foreign antigens (see review [47,48]). They do this
through cell-cell interactions, pinocytosis of the extracellular
matrix and nibbling of other cells membrane [49]. Microglia are
extremely sensitive to even small pathological changes, eliciting
prompt responses by modulating their number, morphology and
cell surface receptors. We observed a marked increase in microglia
cell number (Mac1+) in SN when a-syn was overexpressed, which
agrees with previous observations in mice during a-syn pathology/
neurodegeneration [50,51,52,53,54]. However, gliosis followed
different kinetics depending on the degree of neuropathology: a
rapid high magnitude response (neurodegeneration) or a pro-
longed slower one (cell death). As microglia are a major source of
cytokines and chemokines, the extent and magnitude of the
response is a key element of regulation that could tip the balance
between a beneficial and detrimental response. It is important to
note, that when comparing microglial responses one should take
into account not only numbers, but also profiles and more
importantly the marker used to define microglia. A recent study
reported microgliosis in striatum but not in SN in animals over-
expressing mutated A53T a-syn via rAAV [55]. Here they used
Iba1 as a marker of microglia. Iba1 is a well-documented
microglia specific protein that is often used as an alternative
marker for Mac1. However, while Iba1 is implicated in Ca
binding, Mac1 is an integrin that binds to multiple factors and acts
as a subunit of Complement Receptor 3 [56,57,58]. This means
that we may well be looking at two different scenarios.
A causative relation between extracellular a-syn and activa-
tion of microglia in vitro has been suggested [26,29,59]. In
culture, microglia uptakes and processes a-syn with higher
efficiency than other brain cells [60]. Furthermore, the efficiency
of this process seems to depend on the activation state of the
microglia and if a-syn is in monomeric or oligomeric form
[60,61]. This relationship between a-syn and microglia activa-
tion has also been reported in vivo [50,51,62]. So depending on
the stage of the disease, the type of a-syn present in the cell may
vary, as well as the form it is presented to and/or uptaken by
microglia. This could result in a-syn eliciting different microglial
responses. In fact, our data suggest that the way a-syn is handled
by the cell will determine the type of microglia response. The
induction of distinct protein expression patterns and cell
differentiation, will ultimately lead to specific cytokine profiles
and and cell-to-cell interactions.
In our study the increase in Mac1+ cell number was paralleled
by changes in the distribution of the different cell profiles/types of
the microglial population. Although at long term the total number
of microglial cells return to normal, cell profile/type distribution
was different from that observed in either GFP or contralateral
control, suggesting a persistent activation of the microglia. In the
occurrence of cell death, microglia showed a predominant
macrophagic morphology (Type D) that persisted with time,
which correlated with elevated CD68+ expression (phagocytic
marker). This suggests that above a certain level of a-syn
neuropathology the microglial response in the SN becomes
detrimental. In fact in vitro, co-culture of neurons with macro-
phagic microglia results in increased a-syn modifications and in
turn in dopaminergic cell death [63]. Further supporting this
correlation, when a-syn neuropathology was only apparent in the
striatum, microglia did not express CD68 and cell death was
absent. This differs from a previous work using a similar approach,
where in absence of cell death, a significant increase in CD68+
cells was observed at 4 weeks but not at later time points in
animals expressing a-syn [64]. Interestingly, in their report and in
our hands, CD68 expression peaks at 4 weeks in the GFP group.
Thus, CD68 up-regulation at 4 weeks is probably due to the viral
vector/injection, a response that is resolved already at 8 weeks in
both their and our studies [64]. It is therefore safe to state that the
persistence of CD68+ cells is not related to a vector/injection-
induced response, but rather to the presence of high cellular levels
of human a-syn. It should be noticed as well, that in our approach
cell death was complete by 4 weeks since no further decrease of
TH+ cells in SN was observed beyond this time point. Thus the
persistence of macrophagic microglia, beyond the neurodegener-
ative process, points to the induction of a long-lasting inflamma-
tory response to human a-syn expression.
In PD patients, it has been observed that microglia express
HLA-DR, the human homologue of MHC II [14]. Furthermore,
MHC II expression, but not CD68, has been correlated to a-syn
deposition in surviving cells in SN from PD patients [38]. MHC
II is expressed by antigen presenting cells, which constantly
present antigen of extracellular origin to CD4+ Tc e l l s .I no u rin
vivo model, a-syn induced MHC II expression in the SN
independently of the level of neuropathology. However, animals
lacking overt pathology in SN showed a more robust MHC II
increase, suggesting that its induction is dependent on the
presence of neurons expressing a-syn (whose number was higher
in the a-syn-neurodegeneration group) rather than cell death.
Furthermore, when we investigated the expression of MHC II in
the striatum, we observed that only animals with striatal
neurodegeneration but not cell death (which exhibited higher
density of a-syn+ fibers at all times) showed a consistent up-
regulation of the protein. As fibers decreased in number and
pathological accumulation of a-syn increased, MHC II expres-
sion diminished in these animals. Therefore our data suggest that
MHC II expression correlates with the availability of neurons and
fibers expressing a-syn.
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between T-lymphocytes are altered [66]. Our data suggest that a-
syn can activate the adaptive immune system through MHC II
mediation. If endocytosed by microglia, a-syn could be loaded into
the MHC II complex and then be presented to CD4+ T cells that
will orchestrate the immune response. Indeed, in the MPTP model
microglia proliferation has been shown to precede recruitment of
T cells, suggesting that involvement of the adaptive immune
system is preceded by microglia activation [65]. Accordingly, in
our study, a-syn expression in SN led to the recruitment of T cells.
The number of T cells observed seemed more relevant in animals
presenting cell death, even though MHC II expression was
observed in both groups. We could thus anticipate that the type of
a-syn presented to the T cell is different in each case, therefore
initiating different responses, further supporting the idea that the
form of a-syn present in the brain may determine the type of
response. Accordingly, nitrated a-syn has been shown in vivo to
trigger a detrimental immune response that results in neurode-
generation [33]; while vaccination against unmodified a-syn has
been shown to be protective [67]. Indeed, although both a-syn
expressing groups recruited CD4+ and CD8+ T cells, this
recruitment was retarded in the occurrence of cell death, where
the CD8 response was markedly higher. There is mounting
evidence in vivo that different subtypes of T cells, CD4 vs. CD8
[65] and effector T cells vs. regulatory T cells [32,68], play distinct
roles during PD-like progression. Thus one could envisage that
depending on the type of microglia presenting antigen, which may
be determined by the type of a-syn, different cytokines will be
elicited and these will direct the T cell response along different
pathways.
Overall, we find that a-syn overexpression in the SN
induced a robust early and long lasting microglia activation
that was dependent on the presence of a-syn but not on cell
death. Indeed, the microglial response observed is an event
initiated and sustained by a-syn overexpression that could play
a role in the death or survival of the affected dopaminergic
neurons. In addition our data suggest the involvement of the
adaptive immune system, as shown by MHC II up-regulation
and lymphocyte infiltration. While it is tempting to speculate
about a possible therapeutic intervention by anti-inflammatory
agents targeting the CD68 expressing microglia, at the present
time it is unclear what the roles of these two microglia
populations are (MHC II+ vs. CD68+) and their relation to the
adaptive immune system. Activated microglia has been shown
to release pro-inflammatory cytokines such as IL-6 and TNFa
that could exacerbate neuronal damage. However, it has also
been reported that microglial cells are able to release anti
inflammatory cytokines such as IL-10 or neuroprotective
molecules such as NT3, NGF and BDNF that could play an
important role in neuronal survival (for review see [48,69,70]).
Changes in cytokines and growth factors in PD patients reveal
the existence of a detrimental unbalance between pro-
inflammatory deleterious microglia (expressing IL-1, TNFa
and IL-6) and protective microglia (releasing NGF, BDNF)
[71,72,73]. Our data clearly brings to light the existence of two
distinct microglial responses dependent on the stage of a-syn
induced neuropathology, with MHCII or CD68 up-regulated
differentially. Further studies will be required to address the
role of the different microglia subpopulations during the
neurodegenerative process.
Supporting Information
Figure S1 Cell association with blood vessels. Representative
photos show blood vessels in SN of animals overexpressing a-syn.
In animals where cell death was observed, the cells associated with
blood vessels (counterstained with cresyl blue) were Mac1 low/neg
at 4 weeks (arrowheads in A and B). Mac1+ cells were observed at
4 weeks (C and D) in the a-syn-neurodegeneration group, as well
as, at 8 weeks in both a-syn groups (not shown). Note how Mac1+
microglia seem to extend their processes into the vessel (arrows in
C) or appear in close association with the vessel lumen
(arrowheads in D). Scale: A, B and D, 20 mm (D applies to C).
Found at: doi:10.1371/journal.pone.0008784.s001 (3.50 MB TIF)
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